SCHEMBL6982668

SCHEMBL6982668

O=C(O)[C@H]1O[C@@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N1CCN(c2ccc(F)cc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.60
KDM4E B2RXH2 2/20 0.56
TP53 P04637 1/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
ALDH1A1 P00352 2/20 0.49
GFER P55789 2/20 0.47
ITGA4 P13612 1/20 0.47
MAPT P10636 2/20 0.45
GRM5 P41594 1/20 0.45
LMNA P02545 1/20 0.45
TSHR P16473 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HSD17B10 Q99714 1/20 0.45
PKM P14618 1/20 0.45
ALOX12 P18054 1/20 0.45
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6979423 0.86 KMT2A (0.53) KDM4EMEN1KMT2AALDH1A1MAPT
SCHEMBL6981138 0.85 CAPN1 (0.57) POLBKDM4EKMT2AALDH1A1LMNA
SCHEMBL9088919 0.84 MMP8 (0.53) MEN1KMT2AALDH1A1ITGA4SMN1; SMN2
SCHEMBL27488200 0.84 POLB (0.71) POLBKDM4ETP53MEN1KMT2A
SCHEMBL9091353 0.83 HSD17B10 (0.54) MEN1KMT2AALDH1A1SMN1; SMN2HSD17B10
SCHEMBL6985559 0.80 CAPN1 (0.58) POLBKDM4EALDH1A1GFERHSD17B10
SCHEMBL6983547 0.77 KDM4E (0.63) POLBKDM4ETP53MEN1KMT2A
SCHEMBL9090621 0.76 ITGA4 (0.45) MEN1KMT2AALDH1A1ITGA4TSHR
SCHEMBL9089936 0.76 FPR2 (0.43) TP53MEN1KMT2AALDH1A1TSHR
SCHEMBL9091073 0.76 KMT2A (0.50) MEN1KMT2AALDH1A1ITGA4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6551999-B1 For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
EP-0771565-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
US-6214800-B1 ANGIOGENESIS INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-04-10 US disclosed
US-6057290-A ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS SENJU PHARMACEUTICAL CO., LTD. (JP) 2000-05-02 US disclosed
EP-0928786-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-14 EP disclosed
EP-0927716-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-07 EP disclosed
EP-0838460-A1 PIPERAZINE DERIVATIVES AND USE OF THE SAME Senju Pharmaceutical Co., Ltd. (JP) 1998-04-29 EP disclosed
EP-0771565-A2 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1997-05-07 EP disclosed